RxDoctor Payments Data

Carla Dente, MD

Internal Medicine · Lemoyne, PANPI 1720079122

Payments from drug & device makers

$7,286in general payments, 2019–2025

Across 397 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$784
  • GSK$740
  • Paratek Pharmaceuticals, Inc.$365
  • Exact Sciences$339
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$7,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,286 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$109,074
Medicare patients
258
Services billed
2,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$95,371
MounjaroTirzepatide62$70,745
EliquisApixaban50$63,709
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$25,142
Breo ElliptaFluticasone/Vilanterol24$17,503
XareltoRivaroxaban14$14,667
Rosuvastatin Calcium245$7,355
PremarinEstrogens, Conjugated14$7,163
Verapamil Er PmVerapamil Hcl12$6,105
Atorvastatin Calcium391$5,487
SynthroidLevothyroxine Sodium75$5,278
Losartan Potassium266$4,547
Metoprolol Succinate201$4,471
Levothyroxine Sodium367$4,194
Fentanyl43$3,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$31$95,37191 claims
PfizerEliquis, Premarin$166$70,87264 claims
Lilly USA, LLCMounjaro$784$70,74562 claims
GSKTrelegy Ellipta, Breo Ellipta$740$42,64550 claims
Johnson & JohnsonXarelto$59$14,66714 claims
AbbVieSynthroid$1,068$5,27875 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$4,194367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lemoyne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →